MCPH1 inhibits condensin II during interphase by regulating its SMC2-kleisin interface
- University of Oxford, United Kingdom
- The Institute of Cancer Research, United Kingdom
- Baylor College of Medicine, United States
- Human Technopole, Italy
Abstract
The dramatic change in morphology of chromosomal DNAs between interphase and mitosis is one of the defining features of the eukaryotic cell cycle. Two types of enzymes, namely cohesin and condensin confer the topology of chromosomal DNA by extruding DNA loops. While condensin normally configures chromosomes exclusively during mitosis, cohesin does so during interphase. The processivity of cohesin’s loop extrusion during interphase is limited by a regulatory factor called WAPL, which induces cohesin to dissociate from chromosomes via a mechanism that requires dissociation of its kleisin from the neck of SMC3. We show here that a related mechanism may be responsible for blocking condensin II from acting during interphase. Cells derived from patients affected by microcephaly caused by mutations in the MCPH1 gene undergo premature chromosome condensation but it has never been established for certain whether MCPH1 regulates condensin II directly. We show that deletion of Mcph1 in mouse embryonic stem cells unleashes an activity of condensin II that triggers formation of compact chromosomes in G1 and G2 phases, which is accompanied by enhanced mixing of A and B chromatin compartments, and that this occurs even in the absence of CDK1 activity. Crucially, inhibition of condensin II by MCPH1 depends on the binding of a short linear motif within MCPH1 to condensin II's NCAPG2 subunit. We show that the activities of both Cohesin and Condensin II may be restricted during interphase by similar types of mechanisms as MCPH1's ability to block condensin II's association with chromatin is abrogated by the fusion of SMC2 with NCAPH2. Remarkably, in the absence of both WAPL and MCPH1, cohesin and condensin II transform chromosomal DNAs of G2 cells into chromosomes with a solenoidal axis showing that both cohesin and condensin must be tightly regulated to adjust the structure of chromatids for their successful segregation.
Data availability
HiC sequencing data has been deposited in GEO. (accession number: GSE188988)
-
MCPH1 inhibits condensin II during interphase by regulating its SMC2-kleisin interfaceNCBI Gene Expression Omnibus, GSE188988.
Article and author information
Author details
Lothar Schermelleh
Alessandro Vannini
Funding
Wellcome Trust (107935/Z/15/Z)
- Martin Houlard
- Jonathan Godwin
- Kim Nasmyth
McNair Medical Institute Scholar Award
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
NIH Encyclopedia of DNA Elements Mapping Center Award (UM1HG009375)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
US-Israel Binational Science Foundation Award (2019276)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
Behavioral Plasticity Research Institute (NSF DBI-2021795)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
NSF Physics Frontiers Center Award (NSF PHY-2019745)
- Muhammad S Shamim
- Aviva Presser Aiden
- Erez Lieberman-Aiden
- Lothar Schermelleh
NIH CEGS Award (RM1HG011016-01A1)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
European Research Council (294401)
- Martin Houlard
- Jonathan Godwin
- Kim Nasmyth
Cancer Research UK (26747)
- Martin Houlard
- Jonathan Godwin
- Kim Nasmyth
Wellcome Trust (107457/Z/15/Z)
- Lothar Schermelleh
Wellcome Trust (091911)
- Lothar Schermelleh
Paul and Daisy Soros Foundation
- Muhammad S Shamim
Cancer Research UK (CR-UK C47547/A21536)
- Erin E Cutts
- Alessandro Vannini
Wellcome Trust (200818/Z/16/Z)
- Erin E Cutts
- Alessandro Vannini
Welch Foundation (Q-1866)
- Muhammad S Shamim
- David Weisz
- Aviva Presser Aiden
- Erez Lieberman-Aiden
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#08-133) of the University of Arizona. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Minnesota (Permit Number: 27-2956). All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.
Copyright
© 2021, Houlard et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,889
- views
-
- 421
- downloads
-
- 32
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
MCPH1 inhibits condensin II during interphase by regulating its SMC2-kleisin interface
eLife 10:e73348.
https://doi.org/10.7554/eLife.73348
Further reading
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.
-
- Biochemistry and Chemical Biology
- Microbiology and Infectious Disease
Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.
